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information

Conclusion: Building upon a larger experimentally validated ERE set, the h-ERE algorithm is able
to demarcate better the universe of ERE-like sequences that are potential ER binders. Only 14% of
the predicted optimal binding sites were utilized under the experimental conditions employed,
pointing to other selective criteria not related to EREs. Other factors, in addition to primary
nucleotide sequence, will ultimately determine binding site selection.

interactions

Results: Using the TFBS for the estrogen receptor (ER)D (estrogen response element [ERE]) as a
model system, we extracted EREs from multiple molecular and genomic platforms whose binding
to ERD has been experimentally confirmed or rejected. In silico analyses revealed significant
sequence information flanking the standard binding consensus, discriminating ERE-like sequences
that bind ERD from those that are nonbinders. We extended the ERE consensus by three bases,
bearing a terminal G at the third position 3' and an initiator C at the third position 5', which were
further validated using surface plasmon resonance spectroscopy. Our functional human ERE
prediction algorithm (h-ERE) outperformed existing predictive algorithms and produced fewer than
5% false negatives upon experimental validation.

refereed research

Background: Transcription factor binding sites (TFBS) impart specificity to cellular transcriptional
responses and have largely been defined by consensus motifs derived from a handful of validated
sites. The low specificity of the computational predictions of TFBSs has been attributed to ubiquity
of the motifs and the relaxed sequence requirements for binding. We posited that the inadequacy
is due to limited input of empirically verified sites, and demonstrated a multiplatform approach to
constructing a robust model.
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Background
Estrogen receptors (ERs) are members of the nuclear receptor superfamily of transcription factors, which plays key roles
in human development, physiology, and endocrine-related
diseases [1]. Two ER subtypes, namely ERD (ESR1) and ERE
(ESR2), mediate cellular responses to hormone exposure in
target tissues, and receptors are directed at cis-regulatory
sites of target genes via interactions between the zinc finger
motifs in their DNA-binding domains and specific nucleotide
sequence motifs termed estrogen response elements (EREs).
Specificity protein (Sp)-1 and activator protein (AP)-1 transcription factors are also known to tether with ER and regulate a smaller subset of target genes through Sp1 and AP1
binding sites. The importance of these sites to the overall ER
biologic response remains unclear.
The consensus ERE sequence (5'-GGTCAnnnTGACC-3') was
derived from conserved regulatory elements found in Xenopus and chicken vitellogenin genes and consists of palindromic repeats separated by a three-base spacer to accommodate
interactions with receptor dimers [2,3]. Subsequent characterizations of EREs in additional target genes, however, indicate that the majority of response elements deviate from the
described consensus sequence [4]. Furthermore, ERE-like
sequences are ubiquitous in the human genome, and evidence
for ER binding among the majority of ERE-like sites in estrogen response gene expression studies is apparently absent;
these factors suggest that additional sequence motifs and/or
chromatin features may contribute to the specificity of ER
binding and transcriptional response. Recent efforts to model
better the ERE by using position weight matrices (PWMs [5])
in order to describe all previously published EREs have
resulted in more complete models but with a limited ability to
predict bona fide ER binding [6,7]. We posited that the current major challenge with construction of ERE models is the
limited datasets available, both for experimentally determined ER-bound sites and for ERE-like sites that do not bind
ER.
In addition to compiling the known sites reported in the literature, we pursued a combined experimental and informatics
approach to identify additional ER binding sites and their
associated direct target genes. This information was analyzed
to develop a more faithful model of the ER binding site motifs.
To accomplish this, we applied three experimental strategies
for ER-binding sites discovery. First, we predicted putative
EREs in the promoter regions of direct target genes discovered by microarray analysis [8] and then tested for ER binding at predicted sites of responsive genes by chromatin
immunoprecipitation (ChIP) assays [9]. Second, we surveyed
ER-binding sites in promoter regions of the human genome
by hybridizing fluorescently-labeled ChIP DNA fragments to
high-density oligonucleotide arrays ('ChIP-on-chip') with
probes against about 30,000 proximal promoters (-1 kilobase
[kb] to +0.2 kb relative to the transcription start sites [TSSs]).
Third, we detected ER-binding sites across the genome by

http://genomebiology.com/2006/7/9/R82

Microarray data
(89 putative direct target genes)

ChIP-on-chip

Literature review

(30,000 promoters probed)

Consensus ERE search

ChIP qPCR validation

Training data
ChIP-and-clone
(1006 clones)

h-ERE model
ChIP qPCR validation

Testing data

Figure 1 of ERE discovery and validation for model training and testing
Schematics
Schematics of ERE discovery and validation for model training and testing.
ERE, estrogen response element; ChIP, chromatin immunoprecipitation;
qPCR, quantitative polymerase chain reaction.

ChIP, followed by cloning and sequencing of bound fragments ('ChIP-and-clone'). ERE-like sites that have been validated, for binding and nonbinding, by conventional ChIP
followed by quantitative polymerase chain reaction (qPCR)
using site-specific primers were then used to train and test a
model for functional EREs (summarized in Figure 1). In the
present study, we focused on functional human EREs to minimize potential noise introduced by species-specific variation,
which we have previously observed [8].

Results
Functional estrogen receptor binding sites
We used a combination of literature search and direct experimentation to generate a list of qualified ER-binding sites. In
this study we constrained ourselves to using only sites that
have been validated for the modeling of functional EREs. We
first extracted human ERE sequences that have been experimentally validated in the literature to either bind or not to
bind ER. Klinge [4] and Bourdeau and coworkers [10] each
described EREs that have been validated by electrophoretic
mobility shift assays, transient transfection with reporter
gene constructs, or ChIP assays.
Supplementing the list of confirmed EREs gleaned from the
literature, we experimentally identified functional ER-binding sites using two whole-genome experimental strategies.
The first strategy was to extract candidate ER-binding sites
computationally from a list of putative direct ER target genes.
Eighty-nine putative direct target genes were identified as
genes expressed in MCF-7 cells that were responsive to estradiol treatment, sensitive to inhibition by Faslodex (ICI
182,780), and insensitive to cycloheximide [8]. We then computationally surveyed 3.5 kb regions flanking the TSSs (-3 kb

Genome Biology 2006, 7:R82
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Table 1
Genomic coordinates of ERE-like sequences that have been experimentally validated or rejected as ER-binding

Genomic location

Validation

Reference

PDZK1
ADORA1

chr1:143,215,756-143,215,768

GGTCAcccAGTCC

Binding

This study

chr1:199,790,269-199,790,281

GGTTAgggTGACC

Binding

[10] and this study

ADORA1

chr1:199,790,414-199,790,426

GGTGTcttTGACC

Binding

This study

AGT

chr1:227,156,613-227,156,625

GGGCAtcgTGACC

Binding

[4]

GREB1

chr2:11,603,634-11,603,646

GGTCAaaaTGACC

Binding

[10]

GREB1

chr2:11,615,324-11,615,336

GGTCAtcaTGACC

Binding

[10]

GREB1

chr2:11,621,861-11,621,873

AGTCAgtgTCACC

Binding

This study

GREB1

chr2:11,623,258-11,623,270

GGTCAttcTGACC

Binding

[8,10]

CYP1B1

chr2:38,214,993-38,215,005

GGTCGcgcTGCCC

Binding

This study

Binding

This study

Binding

[10]

AREG

chr4:75,676,340-75,676,352

GGACAaggTGTCC

Binding

This study

ELOVL2

chr6:11,154,748-11,154,760

GGTCAtctTGATG

Binding

This study

VEGF

chr6:43,844,381-43,844,393

AATCAgacTGACT

Binding

[4]

LY6E

chr8:144,170,802-144,170,814

GGACAagaTGACC

Binding

[10]

PTGES

chr9:129,597,654-129,597,666

GGACAgccTGGCC

Binding

This study

CASP7

chr10:115,428,398-115,428,410

GGTCAgggTGAAC

Binding

[10]

CASP7

chr10:115,428,492-115,428,504

GGTCGgggTGAAC

Binding

[10]

CASP7

chr10:115,428,572-115,428,584

GGTCAgggTGAAC

Binding

[10]

CASP7

chr10:115,428,612-115,428,624

GGTCAgggTGAAC

Binding

[10]

CASP7

chr10:115,428,652-115,428,664

GGTCAgggTGAAC

Binding

[10]

CASP7

chr10:115,428,689-115,428,701

GGTCAgggTGAAC

Binding

[10]

CASP7

chr10:115,428,743-115,428,755

GGTCAgggTGAAC

Binding

[10]

CTSD

chr11:1,741,924-1,741,936

GGCCGggcTGACC

Binding

[4]

PGR

chr11:100,504,595-100,504,607

GGTCAccaGCTCT

Binding

[4]

PGR

chr11:100,505,180-100,505,192

GCAGGagcTGACC

Binding

[4]
[10]

GGTCAgccTCACC

Binding

GGACAtcgTGACC

Binding

[10]

ESR2

chr14:63,879,248-63,879,260

GGTCAggcTGGTC

Binding

[4]

FLJ30973

chr15:55,670,850-55,670,862

GGGCAgtgTGGCC

Binding

This study

FLJ30973

chr15:55,671,545-55,671,557

GGTCAcccTGCTC

Binding

This study

ABCA3

chr16:2,319,793-2,319,805

GGTCAcggTGTTC

Binding

[8]

IGFBP4

chr17:35,849,113-35,849,125

GGTCAttgTGACA

Binding

[10]

TRIM25

chr17:52,323,321-52,323,333

GGTCAtggTGACC

Binding

[4], [10]

BCL2

chr18:59,136,673-59,136,685

GGTCGccaGGACC

Binding

[4]

MGC26694

chr19:19,035,118-19,035,130

GTTCAgagTGACC

Binding

This study

GRAMD1A

chr19:40,182,519-40,182,531

GGCCTggcTGACC

Binding

This study

ACTN4

chr19:43,897,093-43,897,105

GGTCActgTGACT

Binding

This study

GPR77

chr19:52,532,131-52,532,143

GGTCActcTGACA

Binding

This study

C3

chr19:6,671,884-6,671,902

GGTGGcccTGACC

Binding

[4]

NRIP1

chr21:15,359,833-15,359,845

GGTCAaagTGACC

Binding

[8]

TFF1

chr21:42,659,626-42,659,638

GGTCCtggTGTCC

Binding

This study

TFF1

chr21:42,659,906-42,659,918

AGCCAagaTGACC

Binding

This study

TFF1

chr21:42,660,106-42,660,118

GGTCAcggTGGCC

Binding

[4]

CRKL

chr22:19,595,695-19,595,707

AGTCAatcTAACC

Binding

This study

TSHB

chr1:115,283,928-115,283,940

GGTCAgctTGACA

Nonbinding

[10]

TXNIP

chr1:142,927,222-142,927,234

GGTCAgtgGGATC

Nonbinding

This study

LOR

chr1:150,045,850-150,045,862

GGTCCaaaGGACC

Nonbinding

This study

Genome Biology 2006, 7:R82
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chr12:6,355,536-6,355,548
chr12:6,513,208-6,513,220

interactions

SCNN1A
GAPDH

refereed research

GGTCAaagCGGCC
GGTCAaggCGATC

deposited research

chr2:38,215,049-38,215,061
chr3:46,481,739-46,481,751

reports

CYP1B1
LTF

reviews

Pattern

comment

Name
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Table 1 (Continued)
Genomic coordinates of ERE-like sequences that have been experimentally validated or rejected as ER-binding

GREB1

chr2:11,622,443-11,622,455

TGCCAccaTGACC

Nonbinding

This study

GREB1

chr2:11,625,143-11,625,155

TGTCAatcTGTCC

Nonbinding

This study

EN1

chr2:119,322,563-119,322,575

GGTTAcccTGAAC

Nonbinding

This study

UGCGL1

chr2:128,563,200-128,563,212

TGTCAaaaTGTCC

Nonbinding

This study

UGCGL1

chr2:128,565,292-128,565,304

TGTCAcatTGAGC

Nonbinding

This study

PLGLB1

chr2:87,884,778-87,884,790

GGTCAgtgTGCCA

Nonbinding

This study

SIAH2

chr3:151,966,545-151,966,557

GCTCAtagTGCCC

Nonbinding

This study

ATP13A3

chr3:195,656,453-195,656,465

GGTCAttaATACC

Nonbinding

This study
This study

CISH

chr3:50,626,609-50,626,621

GGCCAgagGGACC

Nonbinding

LMCD1

chr3:8,517,591-8,517,603

GGCCTgcaTGACC

Nonbinding

This study

FLJ22269

chr4:673,249-673,261

GGGCAgagTGACT

Nonbinding

This study

CCNG2

chr4:78,433,176-78,433,188

GGACAactTGATC

Nonbinding

This study

STC2

chr5:172,689,912-172,689,924

GGGCAatgTGAAC

Nonbinding

This study

IL6ST

chr5:55,327,909-55,327,921

GGTGAgcaTGATC

Nonbinding

This study

PLK2

chr5:57,792,972-57,792,984

GGTTAcagCGACC

Nonbinding

This study

OLIG3

chr6:137,857,308-137,857,320

CGTCAtccTAACC

Nonbinding

This study

FKBPL

chr6:32,206,228-32,206,240

GGCCAgccCGACC

Nonbinding

This study

FKBPL

chr6:32,206,311-32,206,323

CGCCAccaTGACC

Nonbinding

This study

SERPINE1

chr7:100,361,980-100,361,992

GACCAgccTGACC

Nonbinding

This study

SERPINE1

chr7:100,362,938-100,362,950

GGACAagcTGCCC

Nonbinding

This study

SERPINE1

chr7:100,363,852-100,363,864

TGTCAagaAGACC

Nonbinding

This study

TSPAN13

chr7:16,566,080-16,566,092

GATAAgtcTGACC

Nonbinding

This study

BLVRA

chr7:43,570,289-43,570,301

GGTCActcTGGCT

Nonbinding

This study

BLVRA

chr7:43,570,774-43,570,786

AGTCAaccTTACC

Nonbinding

This study

B4GALT1

chr9:33,157,593-33,157,605

GCTCAacgCGACC

Nonbinding

This study
This study

B4GALT1

chr9:33,158,622-33,158,634

GATCAgaaGGACC

Nonbinding

DNAJC1

chr10:22,333,030-22,333,042

GTTCAactTGTCC

Nonbinding

This study

GAD2

chr10:26,545,037-26,545,049

GGTCGcagTGACC

Nonbinding

[10]

CXCL12

chr10:44,202,437-44,202,449

GGTCCagcTGCCC

Nonbinding

This study

CXCL12

chr10:44,203,283-44,203,295

TGTCAaaaTGGCC

Nonbinding

This study

PGR

chr11:100,509,203-100,509,215

AGTCAtgtTGACA

Nonbinding

This study

DGKZ

chr11:46,321,832-46,321,844

GGCCAtgcTGGCC

Nonbinding

This study

CTSW

chr11:65,403,499-65,403,511

GACCAgccTGACC

Nonbinding

This study

C14orf131

chr14:101,872,078-101,872,090

GGCCAacaTGACA

Nonbinding

This study
This study

DLG7

chr14:54,727,987-54,727,999

GGTCGtccAGACC

Nonbinding

ESR2

chr14:63,876,354-63,876,366

GACCAgccTGACC

Nonbinding

This study

THBS1

chr15:37,657,943-37,657,955

GGTCAatcCCACC

Nonbinding

This study

FLJ13710

chr15:69,737,514-69,737,526

AGTCAttgTTACC

Nonbinding

This study

FLJ13710

chr15:69,738,257-69,738,269

GGTCAatgTGCGC

Nonbinding

This study

FLJ13710

chr15:69,738,459-69,738,471

GCTCActtTGTCC

Nonbinding

This study

SH3GL3

chr15:82,077,053-82,077,065

GATCTtgcTGACC

Nonbinding

This study

SMAP-1

chr15:89,278,745-89,278,757

AGTCAatcTGTCC

Nonbinding

This study

ABCA3

chr16:2,321,166-2,321,178

GGTCTtttTTACC

Nonbinding

This study

HCFC1R1

chr16:3,015,149-3,015,161

GACCAgccTGACC

Nonbinding

This study

ADCY9

chr16:4,107,737-4,107,749

GGTCAggcTGGTC

Nonbinding

This study

ADCY9

chr16:4,108,935-4,108,947

GGTGAaaaTGTCC

Nonbinding

This study

CAPNS2

chr16:54,100,244-54,100,256

GGTCCgtcCGACC

Nonbinding

This study

Genome Biology 2006, 7:R82
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Table 1 (Continued)
Genomic coordinates of ERE-like sequences that have been experimentally validated or rejected as ER-binding

CGCCAtgtTGACC

Nonbinding

This study

chr17:35,851,519-35,851,531

GATCActgTAACC

Nonbinding

This study

IGFBP4

chr17:35,853,510-35,853,522

GGTCAtgcTGCCC

Nonbinding

This study

RBBP8

chr18:18,766,140-18,766,152

GGTCAttcTGCTC

Nonbinding

This study

MKNK2

chr19:2,382,491-2,382,503

GGGCAgagTGAGC

Nonbinding

This study

BBC3

chr19:52,426,840-52,426,852

TGTCAttgTGTCC

Nonbinding

This study

BBC3

chr19:52,427,249-52,427,261

GGTCAggcTGGTC

Nonbinding

This study

GPBP6

chrY:169,893-169,905

GCTCAcgaTGACG

Nonbinding

This study

reviews

chr17:2,441,502-2,441,514

IGFBP4

comment

PAFAH1B1

Shown in bold and underlined are nucleotides that deviate from the consensus core ERE. ER, estrogen receptor; ERE, estrogen response element.
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Figure 2 logos
Sequence
Sequence logos. Shown are sequence logos for (a) the 45 ER-binding loci
with 10 bp flanking sequences and (b) 58 ER nonbinding loci with 10 bp
flanking sequences. The logo for the binders exhibited additional signal at
the third bases upstream and downstream of the core palindromic ERE.
bp, base pairs; ER, estrogen receptor; ERE, estrogen response element.

of the consensus site (or its acceptable variants) is required
for the direct binding of the ER dimer to the DNA. However,
it is still unclear whether the core site alone is sufficient to signal activated ER for such binding or whether additional ERbinding signals in the sequences flanking the core can be used
to distinguish binders from nonbinders. An in silico supervised learning experiment was devised to explore these
possibilities.

Genome Biology 2006, 7:R82

information

We modeled the problem of finding additional signals for ER
binding among the sequences surrounding the core ERE as a
binary classification problem (binders versus nonbinders).
The features were position-specific motifs surrounding the
core ERE. In other words, we asked whether there is any
motif (m) within a definitive distance (p) to the core ERE that
could help distinguish the binders from nonbinders. The
robust and versatile naïve Bayesian classification approach
was employed, with binary tuple <m,p> as features, where m
is a k-bp long motif and p is the distance between motif m and
the core ERE. Two sets of experiments were set up. The first
consisted of the core plus its flanking regions, whereas the
second considered only the flanking regions of core ERE. The

interactions

ER is known to interact with the 10 base pair (bp) long consensus ERE (hereafter referred to as the 'core ERE'). Presence

1

refereed research

Ancillary signals for ER binding around the core ERE

2

deposited research

In our second approach, we performed ChIP assays on estradiol-treated breast tumor cells and detected ER-binding sites
using high-density oligonucleotide microarrays (NimbleGen,
Madison, WI, USA) containing probes against proximal promoter regions (-1 kb to +0.2 kb from TSS; 12 probes per promoter) of over 30,000 human known gene and RefSeq
transcripts annotated in the human genome sequence hg16
(July 2003), NCBI build 34 annotation of the UCSC genome
browser. The ChIP-on-chip studies were performed using
duplicate array experiments on the ChIP samples and on
input control DNA. The promoters that appeared among the
top 5% of the binding ratio range (ER antibody versus control) for both replicates, that had at least a 15% increase, and
that were supported by consistent binding ratio enrichment
across more than four probes or additional evidence of ER
regulation from the microarray data were selected. Putative
EREs (allowing for up to two mismatches from the consensus) were then identified in the selected promoters, and some
were further validated by additional ChIP and qPCR (see
Materials and methods, below, for more detail). Out of the
total 28 sites tested, 13 were found to bind ER whereas 15
were not. From the literature sources and experiments
described above, a total of 45 validated ER-binding sites and
58 validated non-ER-binding were identified, all of which
bore close resemblance to the consensus ERE (Table 1). Each
of the 45 binders and 58 non-binders was associated with a
gene and most were located in the genes' upstream regulatory
regions. This list of 103 genes were used as the training set to
assess the significance of ancillary sequence signals beyond
the core ERE that might better predict ER binding.

(a)

reports

to +0.5 kb) of these 89 genes to identify proximate consensus
EREs (allowing for deviations in up to two conserved positions of the consensus motif). Each site was then tested by
ChIP assays and qPCR with site-specific primers to determine
the true nature of ER binding. Eight EREs were found to be
bound by ER, whereas 41 others were not found to be bound
by ER.
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motif length k and the size of flanking regions were similarly
varied in both setups. The goal was to learn whether motifs of
certain length at particular distances from the core could contribute to the discrimination of binders from nonbinders.
Although the results indicated that window size (k) of 1 bp
generally outperformed the rest (Additional data file 1), the
span of flanking regions did not appear to affect significantly
the outcome of the two experiments.

http://genomebiology.com/2006/7/9/R82

(a)
5’-TGTGGCAACTGGGTCATTCTGACCTAGAAGCAAC-3’wildtype
5’-TGTGGCAACTGGGTCATTCTGACCTAAAAGCAAC-3’mutant 1
5’-TGTGGCAACTGGTTCATTCTGATCTAGAAGCAAC-3’mutant 2
5’-TGTGGCAATTGGGTCATTCTGACCTAAAAGCAAC-3’mutant 3
5’-TGTGGGAACTGGGTCATTCTGACCTAGAAGCAAC-3’mutant 4

(b)

These observations suggested that additional signal for ERbinding might lie in the distribution of single nucleotides
adjacent to the core ERE. This hypothesis was initially investigated by visually inspecting the sequence logo [11] constructed from the binders, including their flanking sequences.
Shown in Figures 2a (for ER binders) and 2b (for nonbinders)
are the logos for up to 10 flanking nucleotides. Comparison
between the binders and nonbinders revealed that additional
binding signals potentially came from adjacent nucleotides,
specifically those up to 3 bp flanking the core ERE, which
extended the consensus palindrome. A series of Monte Carlo
runs, performed to estimate the probability that observing
such additional signals could happen by chance alone,
showed that the signals are statistically significant at 3 bp
away from the core motif (Monte Carlo P value = 0.002 and P
value < 0.001; see Materials and methods and Additional
data file 3).
To determine the functionality for the conserved cytosine and
guanine three bases upstream of the first ERE half-site and
downstream of the second ERE half-site, respectively, we
examined the interactions between ER and wild-type and
mutant binding sites using surface plasmon resonance (SPR)
spectroscopy. Purified ER was incubated with either the previously validated ERE (wild-type) adjacent to the GREB1 gene
or mutants containing substitutions in the conserved guanine
(mutant 1), the canonical half-sites (mutant 2), in the conserved guanine and the cytosine in the symmetrical position
upstream of the first ERE half-site (mutant 3; see Figure 3a),
and at the sixth bases upstream of the core ERE (mutant 4;
see Figure 3a) as the negative control. Substitution of the conserved guanine (mutant 1) disrupted ER binding by about
40%, and, as expected, mutations in the consensus half-sites
reduced binding significantly (see Figure 3b). Interestingly,
substitution of the cytosine three bases upstream of the first
half-site with an adenine (Figure 3b, mutant 3), in addition to
the substitution in the conserved guanine adjacent to the second half-site, further diminished binding. As was also
expected, the substitution outside the three bases flanking the
ERE did not perturb the binding significantly. These results
indicate that the conserved guanine outside of the canonical
ERE, discovered by modeling novel ER binding site, is
involved in mediating ER binding to the ERE.

Modeling functional EREs
The model we propose, h-ERE, exploits the above observation
and consists of two PWMs representing the models for bind-

Binding (percentage wt)

120
100
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20
0
wt

mt1

mt2

mt3

mt4

ERE sequence
Figure 3ER binding
Substitution
disrupts
of the conserved guanine outside of the canonical ERE
Substitution of the conserved guanine outside of the canonical ERE
disrupts ER binding. (a) Interactions between ER and wild-type and mutant
EREs were measured by SPR. The canonical ERE is underlined, and the
conserved guanine is indicated by an arrow. Base substitutions are
indicated in bold. (b) Binding of ER to ERE is indicated as a percentage of
binding relative to the wild-type sequence. ER, estrogen receptor; ERE,
estrogen response element; SPR, surface plasmon resonance.

ers and nonbinders. The model relies on a decision tree for
classifying sites into binders or nonbinders, based on the
scores obtained from the individual PWMs. Two sets of 19 bp
sequences, one for binders and the other for nonbinders, were
formed from the core sites plus three adjacent nucleotides.
We further optimized the binding EREs by minimizing the
total entropy of the aligned sites (see Materials and methods),
while augmenting the nonbinding EREs by taking both
strands of the validated nonbinding loci when constructing
the weight matrix.
With this information we constructed a decision tree for the
selection of high-likelihood binding EREs versus nonbinding
EREs. Each matrix was used to calculate the log-likelihood of
a given 19 bp site to be a binder or a non-binder. For each site
two scores can be calculated, the binding score (SB) and nonbinding score (SNB). Complementing the matrices, a decision
tree for distinguishing binders and nonbinders based on SB
and SNB was constructed from all of the training dataset using
the CART algorithm [12] implemented in R, with 100 crossvalidation runs. Figure 4 depicts the resultant tree. Putative
binders are further subcategorized into three groups, from
weak binding (group 1) to strong binding (group 3). Apart
from these groupings, sites whose raw log-likelihood binding
score (SB) is greater than its nonbinding (SNB) scores are
potentially functional sites. Additionally, to reflect the nature
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Currently, three other models have been widely used to predict functional EREs: consensus sequence search (allowing
for certain mismatches), TRANSFAC matrices using MATCH
[13] search algorithm, and Dragon ERE finder [6]. The performance of these models (under different settings) is compared with h-ERE in Table 3. Although h-ERE was not the
most sensitive or the most specific, it offered the best balance
between the two criteria. With the interest of having a single
performance measure that captures the balance between sensitivity and specificity, harmonic means of the two were computed (see van Rijsbergen [14] and Materials and methods).
By this measure, h-ERE offers the best balance in performance, even under different stringency settings.

refereed research

Whole-genome predictions of ER-binding sites
In order to assign specific ERE predictions, we constructed a
decision tree using binding and nonbinding scores from the
PWMs (see Materials and methods). The parameters were
selected to minimize error on the classification of the training
set. We scanned the human genome (UCSC hg17) using the hERE decision tree and detected 38,024 putative sites under
the 'stringent' criteria, including 3607 EREs encoded by Alu

Genome Biology 2006, 7:R82
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In previously described studies conducted to identify EREs,
the analyses have largely focused on the 5' cis-regulatory
regions of direct target genes. However, ChIP analysis of predicted EREs in the extended promoters of 89 putative direct
target genes defined by hormone and inhibitor treatments
and microarray expression data [8] indicated ER binding in
only 9% of the promoter regions from genes apparently
directly regulated by ER. These results suggest that ER may
target binding sites outside of the canonical 5' promoter
regions. Therefore, to discover additional EREs in an unbiased manner and to generate a dataset for testing model performance, we employed the 'ChIP-and-clone' strategy of
cloning precipitated DNA fragments into a bacterial plasmid
vector, followed by direct sequencing of the inserts to identify
ER binding sites. This approach has the potential to sample
any region of the genome, as opposed to PCR-based or microarray-based directed strategies, which target specific sites or
functional regions, respectively. Anti-ER ChIP was performed on nuclear lysates from estradiol-treated MCF-7 cells,
followed by cloning of precipitated binding sites into the pCRBlunt (Invitrogen, Carlsbard, CA, USA) vector. From the ChIP
library, a total of 1006 clones were successfully sequenced
and specifically mapped to the human genome. Based on the
presence of ERE-like sequences or supporting microarray
expression data for ER regulation of the adjacent transcript,

deposited research

In all, given a 19 bp sequence, the proposed h-ERE first
checks whether the core 13 bp nucleotides contains at most
four mismatches to the consensus ERE. Next, based on the
computed PWM scores, predictions can be made based on
four stringency levels: stringent (considers only sites in group
3 to be binders), medium (predicts sites in group 3 and group
2 to be as binders), relaxed (considers sites of groups 1-3 to be
binders), and loose (defines sites whose SB > SNB as binders).

The validation results indicate that ERE-like sequences
remain the predominant feature of functional ER-binding
sites. In the five clones with EREs and supporting microarray
expression data for ER regulation, the validation rate was
100%; for the 23 clones that encode EREs but lack supporting
expression data, the validation rate was 57% (13/23). In contrast, clones for which no ERE-like sequences were detected,
the validation rates were 40% (2/5) and 9% (7/75), respectively, for those with and without supporting expression data
for the adjacent gene. A total of 19 EREs were found in the 18
empirically verified ER-bound clones. Interestingly, the five
validated clones that contain EREs and are adjacent to genes
that were shown to be hormone regulated map to intronic
regions of the target genes. This is consistent with our
hypothesis that ER may bind outside of the 5' cis-regulatory
regions of target genes. Moreover, when we tested ERE-like
sequences in the promoter region of one of the target genes,
SIAH2, we did not detect ER binding, suggesting that the
intronic ERE is the functional ER binding site (data not
shown) for this particular target gene. From this analysis, all
EREs that bind ER and did not bind ER in the validation
experiments were then used to test model performance
(Table 2).

reports

of the validated sites, the model considers sequences whose
core EREs have more than 4 bp mismatches with the consensus ERE, GGTCAnnnTGACC, to be non-binding.

33 clones were selected for subsequent validation by ChIP
and site-specific qPCR. An additional 75 clones were randomly selected from those that have neither EREs nor adjacent transcript expression data for further validation (data
not shown). Thus, a total of 108 clones were validated (five
contained EREs and are supported by microarray expression
data, 23 with only EREs and no supporting expression data,
five supported by microarray but no EREs, and 75 with neither EREs nor expression data).

reviews

Figure 4tree for ERE prediction
Decision
Decision tree for ERE prediction. Group 3 EREs would be predicted to be
the highest likelihood binders of ER. ER, estrogen receptor; ERE, estrogen
response element; SB, binding score; SNB, nonbinding score.
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Table 2
Validation results on genomic loci containing ERE-like sequences identified by sequencing random ChIP fragment from an ER ChIP
library

Nearest gene

Genomic location

NBPF4
C1orf21
SEC15L2
SLC6A6

Pattern

Validation

chr1:108,492,542-108,492,560

ttaGGTCAgctTGTCCcag

Binding

chr1:181,327,606-181,327,624

ctgGGTCAgcaTGACCttc

Binding

chr11:64,942,548-64,942,566

ctgGGGCAtgcTCACCtca

Binding

chr2:72,713,948-72,713,966

ggaGGTCTaggTGACCtcg

Binding

chr3:132,571,914-132,571,932

aggGGTCAtggTGACAtta

Binding

chr3:14,429,604-14,429,622

ctgGGTCActgTGTCCgga

Binding

SIAH2

chr3:151,957,126-151,957,144

acaGGTCAccaTGACCtgg

Binding

SNX24

chr5:122,216,372-122,216,390

cagGGTTAtctTAACCaac

Binding

PKIB

chr6:122,985,938-122,985,956

tttGGTCAtgtGGGCCtga

Binding

chr6:23,720,183-23,720,201

tcgGGTCAtgcTGCCTggg

Binding

BTBD9

chr6:38,337,561-38,337,579

tggGGTCAtggTGACTcct

Binding

SHB

chr9:37,943,504-37,943,522

gcaGGTGGggcTGCCTcca

Binding

SLC38A1

chr12:44,881,783-44,881,801

cagAGTGAactTGACCtga

Binding

SLC38A1

chr12:44,881,800-44,881,818

gagGGTCAtccCAACCcca

Binding

chr16:2,781,142-2,781,160

ccaGGTCGgctTGCCCtta

Binding

chr16:743,678-743,696

atgGGTCActgTGACCcag

Binding

chr17:46,382,536-46,382,554

cccGGACAcgaTGTCCccc

Binding

chr17:54,072,183-54,072,201

cacGGTCAtggTGACCtga

Binding

chr20:54,945,262-54,945,280

gggAGACAcccTGACCtaa

Binding

chr2:222,089,422-222,089,440

cagGTTCAaaaTGACGggt

Nonbinding

STK10

chr5:171,535,283-171,535,301

tgtGGTCTctgTGCCCagg

Nonbinding

KIAA1191

chr5:175,712,328-175,712,346

agaGGCCAgtcTACCCtcc

Nonbinding

RASGEF1C

chr5:179,478,929-179,478,947

gtgGGCCGgccTGGCCtgt

Nonbinding

SORCS1

chr10:108,692,194-108,692,212

cacAGTCAtgcTGACCcca

Nonbinding

chr14:38,648,346-38,648,364

attGGTCAgagTGACAgaa

Nonbinding

TEX14

LOC57149
CEACAM6

chr14:79,636,926-79,636,944

accTGGCAcgcTGACCcat

Nonbinding

chr16:20,819,825-20,819,843

tggGGTCAcacAGGCCcgt

Nonbinding

chr16:25,535,373-25,535,391

ttaGTTCAcctTAACCcct

Nonbinding

chr19:46,954,305-46,954,323

cagGACCAgggAGACCtga

Nonbinding

Shown in bold and underlined are nucleotides that deviate from the consensus core ERE. ChIP, chromatin immunoprecipitation; ER, estrogen
receptor; ERE, estrogen response element.

repeats. To assess further the performance of our predictive
algorithm, we randomly selected 60 sites predicted to be ER
binders by h-ERE (group 3 sites) and 60 nonbinders (group 0
sites) for further experimental validation by ChIP and qPCR.
Of the 120 sites, specific primers for qPCR could be designed
for only 64 sites, 44 of which are binders whereas 20 are nonbinders. Fourteen per cent (6/44) of the predicted binding
sites were shown to bind ER (more than twofold enrichment
over control) whereas no binding was detected in any of the
sites classified as nonbinders (0/20), suggesting that the
false-negative rate is less than 5%. The low rate of false negatives allows us to demarcate in the human genome the global
set of EREs that contain the universe of putative true binding
motifs. This suggests that, taking into account the 14% validation rate, there would be 5363 validated ER-binding sites
within the global optimized ERE set for the MCF-7 cells,
under conditions similar to our experimental setup.

We then considered how much of the predictions could be
attributed to random occurrences simply by chance alone. A
series of Monte Carlo simulations were carried out to estimate the false positive rate of h-ERE. One thousand nucleotide sequences 1 megabase (Mbp) long were generated
randomly, governed by the empirical single nucleotide distribution of the human genome (UCSC hg17), and were run
through h-ERE. The numbers of predicted binders divided by
1 Mbp was reported as the h-ERE false discovery rate per base
pair. Taking a conservative estimate of the noise and extrapolating it, for the human genome (about 3 gigabases [Gbp])
about 33,000 (approximately 86%) were estimated to be false
positives, and hence approximately 5000 ER-binding sites
are present in the human genome.
Taken together, the convergence of these two analyses suggest that binding site motifs will be subject to statistical noise
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Table 3
Performance comparison of various prediction algorithms for ER binding using the independent dataset shown in Table 2

Sensitivity

Specificity

Harmonic mean

Fisher's exact test P value

Consensus ERE with d2 mismatches 94.74%

30%

45.57%

0.104838

Consensus ERE with d3 mismatches 94.74%

0%

0.00%

1

68.42%

40%

50.49%

0.477589

TFAC 8.1 (min FP)

31.57%

100%

47.99%

0.057117

TFAC 8.1 (min FN)

78.94%

40%

53.10%

0.255439

h-ERE (stringent)

42.10%

90%

57.37%

0.084693

h-ERE (medium)

68.42%

70%

69.20%

0.056272

h-ERE (relaxed)

73.68%

70%

71.79%

0.03043

h-ERE (loose)

84.21%

70%

76.45%

0.006199

reviews

Dragon ERE finder v2.0

comment

Prediction algorithm

h-ERE outperformed the other algorithms. ERE, estrogen response element.

Discussion
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Previous efforts to characterize the ERE have included mutagenesis studies and electrophoretic mobility shift assays or
DNase footprinting experiments. For example, Driscoll and
colleagues [15,16] demonstrated that single mutations in the
core ERE can greatly disrupt ER binding. Furthermore, they
found that changes in the flanking sequences can also either
enhance or disrupt binding, depending on corresponding
changes in the core ERE. Their experiments examined up to
two bases flanking the core ERE, and they found that an A or
T in the position immediately flanking the core ERE is important for optimal ER binding. Their observation is supported
by the model we present here (Figure 2). In our study we
found additional single nucleotide features flanking the consensus ERE that are associated with binding site functionality. In particular, there is a prevalence of guanines in the third
position downstream (or equivalently cytosines in the third
position upstream) of the core ERE motif in binders but not
in the nonbinders. The functional significance of these newly
discovered conserved bases were verified by SPR analysis of
ER interaction with wild-type and mutant binding sites (Figure 3). These additional features were included in the h-ERE
decision tree and probably contributed to improved model

A genome-wide scan for putative functional EREs using the
h-ERE models yielded more than 38,000 predicted highprobability ER binding sites (group 3), which we have shown
should represent the set of all high-likelihood ER-binding
EREs. Experimental validation of randomly selected predicted sites indicated that 14% of the sites bound ER under
the conditions tested, which agreed with the conservative
estimate of an approximate 86% false discovery rate for ERElike sequences in the human genome. From the two
approaches, we project there to be approximately 5000 functional ER-binding sites in the MCF-7 genome. That only one
out of seven of the high-likelihood binding EREs are
functionally used may be attributed to several possibilities.
First is that flanking sequences more distal than where
assessed in the present study may contribute to the selection
of a functional ERE. For example, the nature of the chromatin
around the ERE, the relative location of basal transcriptional
complexes, and the density of adjacent binding of other transcription factors are candidate modulators of ER-binding site
selection. Second, we only tested for ER binding using one
standard condition and in a single breast tumor cell line. It is
probably the case that certain tissue-specific and conditionspecific binding events are modulated by the presence or
absence of ER co-regulators and epigenetic modifications.
The MCF-7 cell line is known to have high levels of ER and to
over-express of AIB1 (amplified in breast cancer 1), which is a
specific co-regulator of ER [17]. Moreover, cancer cell lines
have accumulated many genetic rearrangements and point

deposited research

In this report we describe a combinatorial experimental
approach for transcription factor binding site discovery and
demonstrate superior performance of the resultant computational model. The experimental strategies presented here
address the major problem in binding site modeling, namely
the small size of experimental datasets for model training and
testing. The unique use of validated nonbinding EREs and
examining flanking sequences allowed us to identify a novel
feature of the ERE.

performance. Having both the binding and the nonbinding
ERE sequences enabled us to assess the sensitivity and specificity of the h-ERE model as compared with the consensus
sequence, TRANSFAC database ERE PWM [7], or the previously published Dragon ERE model [6]. Under the four
stringency parameters tested, the h-ERE model exhibited the
optimal combination of sensitivity and specificity, as measured using the harmonic means of these two factors, with 4468% improvements over the other models.

reports

from random motif generation, but that a consistent number
of bona fide binding sites, for the MCF-7 cells and under similar conditions as our experimentations, is likely to exist
(about 5000).
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mutations in their passages, which would further confound
the results by rendering good binding sites inactive.
In our strategy, the approximately 38,000 high-likelihood
ER-binding sites were identified using a training set biased to
the 5' cis-regulatory regions of genes. However, when we
mapped these approximately 38,000 candidate sites to the
genome, only 1821 (about 4.78%) resided within 5 kb
upstream and 500 bp downstream of the TSS. The majority
(about 36.5%) fell inside genes, about 21.4% were within 100
kb upstream of the TSSs, whereas about 21.3% were located
up to 100 kb downstream of the 3' terminus. Approximately
20% were mapped to pure intergenic regions. These findings
suggest that the standard mode of identifying transcription
factor binding by concentrating on immediate cis-regulatory
elements will be unrewarding. In addition, these data collectively question the assignment of physiologic functionality to
an ERE site using only gel shift and transient transfection
assays with the extracted element, because these in vitro
approaches ignore many of the relevant physiologic
conditions.
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no apparent functional divergence of the cognate regulated
genes. With the binding site database that we present here,
such hypotheses can now be computationally examined with
increased confidence.

Conclusion
The availability of larger experimentally validated binding
site sets allows the construction of more robust binding site
prediction algorithms. The proposed h-ERE algorithm
employed genome-wide binding site data collected from various types of experiments. It outperformed other existing
algorithms for predicting ER binding. That only 14% of the
predicted optimal binding sites were utilized under the experimental conditions suggests that there are other selective criteria not related to ERE. Overall, although h-ERE is able to
demarcate better the universe of ERE-like sequences that are
potential ER binders, factors other than primary nucleotide
sequence will ultimately determine binding site selection.

Materials and methods
Previously, we found that many functional ERE binding sites
around responsive genes are poorly conserved between
human and mouse [8]. Moreover, both evolutionarily conserved and nonconserved ERE sites appeared to be equally
functional for ER binding in ChIP assays; therefore, there
appears to be little advantage in using evolutionary history to
identify functional EREs. For this reason, we did not take
ERE conservation across species into consideration, as was
introduced by Jin and colleagues [18] in their recent report.
Instead, we focused on the rules governing functional ER
binding in the human genome.
Our observations raise the intriguing possibility that evolution of estrogen response relies on having a large pool of highquality candidate EREs widely scattered in the genome, some
of which are potentially generated by transposable elements
(about 9% of high-likelihood EREs were within Alu elements). With mutational drift and under evolutionary pressures, different binding sites around the same genes could be
alternatively used and would not have detrimental effects on
overall survival. If these alternative binding cassettes prove
beneficial to the organism, then these secondary sites will
undergo further positive mutations to enhance the ER interaction. Conservation of mechanisms and functions across
species may be a reasonable assumption for highly conserved
biologic processes. However, in the case of EREs and estrogen
functions in development and physiology, phenotypic and
experimental analysis suggest species-specific mechanisms
and hormone responses, including binding site usage. Therefore, using conservation as a filter for function is likely to
introduce a significant number of false-negative findings in
ERE predictions. This view is further supported by two recent
studies [19,20] that found that many functional transcription
factor binding sites are not conserved in evolution but there is

Identification of additional functional EREs
To enlarge the set of validated EREs, we employed a twopronged approach: ChIP-qPCR validation of putative ERE in
the promoters of putative direct target genes; and ChIP-qPCR
validation of putative ERE found in promoters identified
from ChIP-chip experiment (GEO series ID: GSE5405).
For the first approach, we took the 89 putative direct target
genes identified earlier in a gene expression microarray study
[8], extracted their 3.5 kb extended promoter regions, and
scanned the sequences for ERE-like motifs, allowing for up to
two-base variation from the consensus ERE. Only those with
specific PCR primers flanking the EREs were included in
ChIP validations by qPCR. There were 49 EREs from 35 promoters hat met the above criteria. Of these, eight EREs from
seven putative direct target genes were validated to bind ER
and the remaining 41 EREs did not bind ER under the experimental conditions tested in this study.
In the second experiment, the ChIP-chip experiments, only
promoters appearing among the top 5% of both replicate
experiment were selected, amounting to 196 promoters
(binomial P value = 1.42 × e-33). We further increased the
stringency by requiring at least a 15% increase of the IP
(immunoprecipitation) over the input control in two consecutive probes to further filter out potential noise in the system.
This resulted in 111 promoters that met the selection criteria.
Out of the total 111 promoters, we performed ChIP and qPCR
validation on 28 promoters that bore putative EREs and had
either microarray data supporting their regulation by ER or
had consistent binding across consecutive probes (more than
four). Of these, 13 were validated to bind ER and 15 did not
bind ER.
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To detect and identify whether additional ER-binding signals
were flanking the core ERE site, an in silico experiment was
devised. We considered whether the surrounding sequences
of core ERE sites can be used to distinguish binders from nonbinders. A naïve Bayesian classification [12] approach was
employed, with binary tuples <m,p> as the feature, where m
is a motif that is k bp long and p is the location of motif m relative to the core. One can imagine constructing, for each
sequence S, a binary matrix M, with m as the row index and p
as the column index, and the value Mm,p indicates whether
motif m is present at position p. Such a matrix can be built by
running a fixed window of size k over the sequence S and noting down the location of each motif. The class of sequence S,
whether it is a binder (B) or nonbinder (NB), can be predicted
through the equation C(S) below. In our set of experiments, k
was varied from 1 to 5 bp. During the training, the probability
distribution was constructed from the raw motif frequency
counts with Laplacian smoothing of adding pseudocount L to
the raw count.

deposited research

⎞
⎛
C(S) = arg max ⎜ Pr(S | T ) = ∏ Pr( Mm,p | T ) ⎟
m,p
⎠
T ∈{B, NB}⎝
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A cross-validation like supervised classification experiment
was performed upon a sequence set, grouped into two or
more distinct classes, by randomly splitting the sequences
into 4:1 training and test sets, training the classifier using the
training set, and reporting the accuracy of the trained classifier over the test set. One hundred runs of such training/testing were carried out and the accuracy was averaged out. The
figure in Additional data file 1 summarizes the outcomes
under varied parameter settings.
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Biotinylated ERE strands (5'-end labeling) and the antistrands were annealed to form DNA duplexes. The DNA
duplexes were then immobilized on the SPR disk (gold-coated
glass) using biotin-streptavidin-biotin bridge chemistry. Protein was then applied to bind to the immobilized DNA. The
end attachment of DNA ensured sufficient strand flexibility.
For DNA immobilization, the gold disks were first cleaned in
a ultraviolet/ozone chamber for 5 min, followed by immersing in hot piranha solution (a 3:1 mixture of H2SO4 and H2O2)
for 2 min. After rinsing with de-ionized water and drying
using nitrogen, the disks were immersed overnight in a binary
biotin-containing thiol mixture (10% biotin-thiol and 90%
ethylene glycol-thiol at a net concentration of 1 mmol/l in ethanol). After rinsing with ethanol followed by a drying step
using nitrogen, the disks were ready for streptavidin (Sigma,
St. Louis, MO, USA) immobilization (0.1 mg/ml in phosphate-buffered saline) and subsequent biotinylated DNA
assembly (1 Pmol/l in phosphate-buffered saline). ERD (58708 nmol/l in 40 mmol/l HEPES-KOH binding buffer [pH
7.4], containing 10 mmol/l MgCl2, 200 mmol/l KCl, 0.2% Triton X-100, 2 mmol/l DTT) was then applied to bind to the
immobilized DNA. After one cycle of protein binding (about
25 min), 0.1% sodium dodecyl sulfate solution was applied to
disassociate the protein-DNA complex and to expose the
immobilized DNA for new cycles of ER binding.

Probing for auxiliary signals around core ERE

reports

SPR analysis of ER-ERE binding

The SPR measurements were conducted using a double channel, AutoLab ESPR (Eco Chemie, Utrecht, The Netherlands).
In a kinetic measurement mode, molecular adsorption on the
gold disks was detected as SPR angle shifts ('T in mDeg) over
time. The measured 'T was proportionally related to the
amount of adsorbed material, with a mass sensitivity of 120
mDeg = 100 ng/cm2 for protein and DNA. The AutoLab SPR
equipment was equipped with a two-channel cuvette, with the
sensor disk forming the base of the cuvette. Two DNA strands
(50 Pl) were then immobilized in different channels, allowing
protein binding to two different DNA sequences to be monitored in parallel. The measurements were conducted at room
temperature and the noise level was 0.2 mDeg. It is worth
noting that the SPR experiment were done under varying concentrations of ERD, and the reported relative binding affinities of Figure 3 were averages obtained from the varied
concentration of ERD. The same overall relative profiles were
observed for the different mutants.

reviews

MCF7 cells were estrogen deprived for 24 hours and treated
with 10 nmol/l of estradiol for 45 min prior to 1% formaldehyde treatment to crosslink the transcription machinery and
the chromatin. Immunoprecipitations were carried out
overnight with anti-ERD (HC-20) or irrelevant control antiglutathione S-transferase (GST) antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and protein A-sepharose
beads (Zymed, San Francisco, CA, USA). Washing and extraction protocols were modified from methods described previously [9], and PCR reactions were carried out in an ABI Prism
7900 sequence detection system (Applied Biosystems, Foster
City, CA, USA). Forty cycles of PCR were carried out on precipitated DNA and control input DNA. Amplification products were also assayed for specificity by melting curve
analysis at the end of each run. Relative quantifications were
carried out by building standard curves for each primer set
and using genomic DNA, similar to the input, as the template.
Enrichment of ER binding was determined by comparing the
relative quantities of anti-ER and control anti-GST products.
Sites with more than twofold enrichment over control were
considered to be bound by ER (or 'binders').
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Altogether, the study validated 21 EREs to be bound by ER
and 56 EREs not to be bound by ER. They are indicated by the
words 'this study' or by the citation of reference 8, respectively, in the references (right-most) column of Table 1.
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Assessing the significance of flanking nucleotide
positions
Outcomes of the previous experiments indicated that single
nucleotides surrounding the core ERE motif might carry
additional discriminating power between binding and nonbinding EREs. In particular, complementary distinguishing
nucleotides appeared to be present at the third base pairs
after the core ERE, under visual analysis using sequence logos
(Additional data file 2). We designed and carried out a Monte
Carlo experiment to quantify its significance. Employing
information entropy, or roughly the degree of randomness, as
the statistics for each nucleotide position, we asked whether
the surrounding nucleotide positions of arbitrary ERE-like
sites (up to two mismatches to the consensus) in the human
genome contains more information (less random or lower
entropy) than those observed surrounding the 45 binding
EREs. The exact formula for information entropy is as
follows:

∑

H( s) = −

x ={A ,C ,G ,T}

f x log 2( f x )

Where s is the set of nucleotides and fx is the frequency of
nucleotide x in the set s. Let sn be the set of nucleotides found
n bp from the core ERE motif. For each flanking nucleotide up
to 5 bp upstream and downstream, denoted as n = '-5' to n =
'+5', we took 45 random loci flanking the ERE-like sites in the
genome and computed its entropy. This was done 1000 times
and the fraction of times it was lower than the observed
entropy for the corresponding position of the 45 binding
EREs was reported as the estimated P value (Additional data
file 3).

Optimizing the sequence set for model building
With the assumption that bindings most probably occur only
on one of the strands and that nonbindings mean that none of
the strands were bound, we opted to optimize the binder and
nonbinder PWMs by minimizing the total information
entropy of the binders while augmenting the nonbinder
sequence set by taking both strands of the validated nonbinding loci. The total information entropy (TE) can be calculated
as follows:

⎛
∑ ( fx ,i log 2( fx ,i ) ) ⎞⎟
TE( F ) = −∑ ⎜
x ={A ,C ,G ,T}
⎠
⎝
i =1
N

Where F is a 4 × N matrix of relative frequency of each nucleotide at each position, which can be derived from the PWM of
the aligned sites. The overall entropy of the binders was minimized through selectively reverse complementing some of
the binders using a greedy hill-climbing approach, which
resulted in 15 binder sequences being reverse complemented.

http://genomebiology.com/2006/7/9/R82

propose the use of a single measure to evaluate the balanced
performance between specificity and sensitivity. One simple
option is to calculate the arithmetic mean of specificity and
sensitivity. Arithmetic means, however, might be misleading
when rates are being averaged. Inspired by the usage of the Fmeasure [14] in the field of information retrieval, calculated
as the harmonic mean of precision and recall, we opted for
using harmonic mean to quantify the balance between sensitivity (sn) and specificity (sp), which can be easily calculated
using the following equation:

G( sp, sn) =

2 ∗ sp ∗ sn
sn + sp

Estimating the amount of false positives
A pertinent question any high-throughput in silico prediction
scheme is the degree of false positivity. The number of falsely
predicted binding sites, from among the 38,024 predicted
sites in the human genome (about 3 Gbp), we devised a Monte
Carlo simulation to estimate the distribution of false-discovery rate. Nucleotide sequences of 1 million base pairs long
were generated by drawing random nucleotides from the
same nucleotide distribution as the human genome (UCSC
hg17). The sequences were then run through the h-ERE. Sites
on the random sequences predicted to be binders by the hERE represent the false positives. As the single nucleotide
based random sequence generation may not faithfully reflect
all the inherent properties of the human genome, conservative estimation the false-positive rate was made, by reporting
the 99th percentile. The above simulation was iterated 1000
times to approximate the rate of false positives per million
base pairs. At the 99th percentile, the false positive rate was
11 false binders per million base pairs. This is roughly 33,000
false positive sites for the approximate 3 Gbp human genome,
or about 86% of the total approximately 38,000 predicted
binders.

Additional data files
The following additional data are available with the online
version of this paper. Additional data file 1 is a document
summarizing the results of preliminary Naïve Bayesian analysis on the validated binding sites and their immediate surrounding sequences. Additional data file 2 is a document
showing the sequence logos for the final binder and nonbinder sets. Additional data file 3 is a document tabulating
the Monte Carlo P values for the information entropy significance of each base pair location immediately flanking the core
ERE.
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A balanced measure based on sensitivity and specificity
The trade off between achieving high sensitivity and high specificity for a prediction system is well appreciated. Here, we
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